MedTrace Logo

Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts

NCT04290572 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2020-03-03

No results posted yet for this study

Summary

Randomized clinical trial to compare the efficacy of different doses of oral isotretinoin 10 mg/day, 20 mg/day and 30 mg/day during 12 weeks for the treatment of facial recalcitrant flat warts. The primary endpoint will be the proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.

Conditions

  • Flat Wart

Interventions

DRUG

Isotretinoin capsules

Jelly capsules of isotretinoin

Sponsors & Collaborators

  • Centro Dermatológico Dr. Ladislao de la Pascua

    lead OTHER

Principal Investigators

  • María Guadalupe Olguín-García, M.D.,MSc. · Centro Dermatológico Dr. Ladislao de la Pascua

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-15
Primary Completion
2023-02-28
Completion
2023-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04290572 on ClinicalTrials.gov